journal Journal For International Medical Graduates Journal For International Medical Graduates California Institute of Behavioral Neurosciences and Psychology US https://www.cibnp.com 2832-9864 117 Articles The Symphony of Survival: Sacubitril/Valsartan’s Heartfelt Impact on Mortality in Heart Failure: A Systemic Review Eshwar Kumar Burra Burra Eshwar Kumar eshwar.kumar.burra@jimgs.com Kamran Shahid Shahid Kamran kamran.shahid@jimgs.com Yonas Tamene Tamene Yonas yonas.tamene@jimgs.com Shefali P. Mody Mody Shefali P. shefali.p.mody@jimgs.com Kaiser O. Sadiq Sadiq Kaiser O. kaiser.o.sadiq@jimgs.com Yogamba M. Shivakumar Shivakumar Yogamba M. yogamba.m.shivakumar@jimgs.com 05 09 2023 Received: 592023 Copyright (c) 2023 Journal For International Medical Graduates 2023 Journal For International Medical Graduates Heart failure (HF) Sacubitril/valsartan Reduced ejection fraction (HFrEF) Clinical trials & outcomes Patient selection & monitoring Berg DD, Braunwald E, DeVore AD, et al. Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. JACC Heart Fail. 2020;8(10):834-843. doi:10.1016/j.jchf.2020.06.008 Berg DD, Samsky MD, Velazquez EJ, et al. Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. Circ Heart Fail. 2021;14(2):e007034. doi:10.1161/CIRCHEARTFAILURE.120.007034 Mann DL, Greene SJ, Givertz MM, et al. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial [published correction appears in JACC Heart Fail. 2020 Dec;8(12):1059]. JACC Heart Fail. 2020;8(10):789-799. doi:10.1016/j.jchf.2020.05.005 Mann DL, Givertz MM, Vader JM, et al. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA Cardiol. 2022;7(1):17-25. doi:10.1001/jamacardio.2021.4567 McMurray JJ, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013;15(9):1062-1073. doi:10.1093/eurjhf/hft052 Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381(17):1609-1620. doi:10.1056/NEJMoa1908655 Vaduganathan M, Claggett BL, Desai AS, et al. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. J Am Coll Cardiol. 2020;75(3):245-254. doi:10.1016/j.jacc.2019.11.003 Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381(17):1609-1620. doi:10.1056/NEJMoa1908655 Spannella, F., Giulietti, F., Filipponi, A., & Sarzani, R. (2020). Effect of sacubitril/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials. ESC heart failure, 7(6), 3487–3496. https://doi.org/10.1002/ehf2.13002 Greene, S. J., & Fonarow, G. C. (2023). Targeting sacubitril/valsartan for heart failure with mildly reduced or preserved ejection fraction. European heart journal, ehad427. Advance online publication. https://doi.org/10.1093/eurheartj/ehad427 Linden, K., Mailey, J., Kearney, A., & Menown, I. B. A. (2020). Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials. Advances in therapy, 37(6), 2620–2645. https://doi.org/10.1007/s12325-020-01355-5 Huo, Y., Li, W., Webb, R., Zhao, L., Wang, Q., & Guo, W. (2019). Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study. Journal of clinical hypertension (Greenwich, Conn.), 21(1), 67–76. https://doi.org/10.1111/jch.13437 Lin, J., Zhou, J., Xie, G., & Liu, J. (2021). Efficacy and safety of sacubitril-valsartan in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials: A PRISMA-compliant article. Medicine, 100(52), e28231. https://doi.org/10.1097/MD.0000000000028231 Martin, N., Manoharan, K., Davies, C., & Lumbers, R. T. (2021). Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. The Cochrane database of systematic reviews, 5(5), CD012721. https://doi.org/10.1002/14651858.CD012721.pub3 McMurray, J. J. V., Jackson, A. M., Lam, C. S. P., Redfield, M. M., Anand, I. S., Ge, J., Lefkowitz, M. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., Rizkala, A. R., Sabarwal, S. V., Shah, A. M., Shah, S. J., Shi, V. C., van Veldhuisen, D. J., Zannad, F., Zile, M. R., … Solomon, S. D. (2020). Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. Circulation, 141(5), 338–351. https://doi.org/10.1161/CIRCULATIONAHA.119.044491 Salah, H. M., Fudim, M., Al'Aref, S. J., Khan, M. S., Almarzooq, Z. I., Devabhaktuni, S. R., Mentz, R. J., Butler, J., & Greene, S. J. (2021). Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. The American journal of cardiology, 145, 165–168. https://doi.org/10.1016/j.amjcard.2021.01.013 Savarese, G., Hage, C., Benson, L., Schrage, B., Thorvaldsen, T., Lundberg, A., Fudim, M., Linde, C., Dahlström, U., Rosano, G. M. C., & Lund, L. H. (2021). Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry. Journal of internal medicine, 289(3), 369–384. https://doi.org/10.1111/joim.13165 Tai, A., Ambrosy, A. P., & Fudim, M. (2021). Making the case for sacubitril/valsartan in patients with heart failure with a preserved ejection fraction. European heart journal. Cardiovascular pharmacotherapy, 7(3), e5–e6. https://doi.org/10.1093/ehjcvp/pvab007 Page MJ, McKenzie JE, Bossuyt PM, et al.: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J. 2021, 372:n71. 10.1136/bmj.n71